For the pharmaceutical industry caught in the crosshairs of a potential trade war, the consequences of U.S. tariffs on China ...

Carrying out his campaign promises to reform government, President Donald Trump signed 46 executive orders (EOs) between Jan. 20-31 that have been published in the Federal Register. Of those, 26 were ...

Melanoma is the most aggressive form of skin cancer and often spreads to the brain. Though immunotherapy has greatly improved ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Europe has more oncology startups than the U.S., but many more U.S. companies scale up to the later growth stage. Given the ...

As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer, lacking targeted therapies due to its molecular characteristics. Tumor-associated ...

BioWorld’s three-part analysis of M&As sought to discover successful transactions and to understand the trend of multibillion-dollar deals that have become commonplace in the last decade. Instead, ...

Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).

The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to ...